

TABLE OF CONTENTS

1 TABLE OF CONTENTS

.....	3
2 SYNOPSIS OF PROPOSED STUDY	6
3 LIST OF ABBREVIATIONS AND DEFINITION OF STUDY SPECIFIC TERMINOLOGY	9
4 INTRODUCTION AND RATIONALE FOR THE STUDY	11
4.1 INTRODUCTION	11
4.1.1 <i>Previous studies with the drug</i>	13
4.1.2 <i>Ongoing studies with the drug</i>	15
4.2 RATIONALE FOR TREATMENT OF TYPE 1 DIABETES I IN THIS WAY	16
4.3 RATIONALE FOR USE OF THE PROPOSED ADMINISTRATION ROUTE.....	17
5 RISK-BENEFIT ANALYSIS	18
5.1 RISKS OF drug nr 1	18
5.2 RISKS OF drug nr 2	18
5.3 RISKS OF COMBINING Drug 1 and 2	19
5.4 JUSTIFICATION – RISK-BENEFIT	19
6 TRIAL OBJECTIVES AND PURPOSE	20
6.1 AIM OF PRESENT STUDY	20
6.2 PRIMARY OBJECTIVE	20
6.3 SECONDARY OBJECTIVES	20
6.4 ENDPOINTS	20
6.4.1 <i>Primary Endpoint</i>	20
6.4.2 <i>Secondary Endpoints</i>	20
7 TRIAL DESIGN	22
7.1 DESCRIPTION OF THE STUDY DESIGN AND PROCEDURES	22
7.1.1 <i>Study Procedures</i>	25

7.2 PATIENT DIARY	29
7.3 STUDY STOPPING CRITERIA	29
7.4 DECISION CRITERIA	30
7.5 MANAGEMENT OF THE DISEASE	30
7.6 DATA SAFETY MONITORING BOARD	30
8 STUDY POPULATION	31
8.1 INCLUSION CRITERIA	31
8.2 EXCLUSION CRITERIA	31
8.3 RECRUITMENT AND SCREENING	32
8.4 PATIENT WITHDRAWAL CRITERIA	32
8.5 PATIENT WITHDRAWAL	32
9 STUDY ASSESSMENTS	35
9.1 ASSESSMENT OF VARIABLES OF DIABETES STATUS	35
9.1.1 <i>Mixed Meal Tolerance Test</i>	35
9.1.2 <i>Hemoglobin A1c</i>	35
9.1.3 <i>Fasting Glucose and Fasting C-Peptide</i>	35
9.1.4 <i>Glycemic Fluctuations/Variability</i>	35
9.2 ASSESSMENT OF SAFETY VARIABLES	36
9.2.1 <i>Adverse Events</i>	36
9.2.2 <i>Physical Examination</i>	36
9.2.3 <i>Neurological Examination</i>	37
9.2.4 <i>Vital Signs</i>	37
9.2.5 <i>Laboratory Safety Assessments</i>	37
9.3 IMMUNE SYSTEM ASSESSMENTS	38
9.3.1 <i>Antibody Titer</i>	38

9.3.2 <i>Bioanalytical Method</i>	
38	
9.4 ASSESSMENT OF GENETIC STATUS	39
9.5 MEASUREMENT OF VITAMIN D STATUS	39
9.5.1 <i>Blood Sampling Procedures</i>	
39	
9.6 ASSESSMENT OF QUALITY OF LIFE.....	39
9.7 OTHER ASSESSMENTS	39
9.8 DEMOGRAPHICS AND OTHER BASELINE CHARACTERISTICS	39
9.8.1 <i>Demographics and Baseline Data</i>	
39	
9.8.2 <i>Medical History</i>	
40	
9.8.3 <i>Family History of T1D</i>	
40	
10 TREATMENT OF PATIENTS	41
10.1 STUDY TREATMENT	41
10.1.1 <i>Method of Assigning Patients to Treatment Groups</i>	
41	
10.1.2 <i>Blinding and Code Breaking</i>	
41	
10.1.3 <i>Study Medication</i>	
42	
10.1.4 <i>Supply, Packaging, Handling and Storage</i>	
43	
10.2 TREATMENT COMPLIANCE	43
10.3 STUDY MEDICATION ACCOUNTABILITY	43
10.4 CONCOMITANT THERAPY	44
10.5 POST STUDY TREATMENT	44
11 ADVERSE EVENTS	45
11.1 DEFINITIONS OF ADVERSE EVENTS (AE)	45
11.2 SERIOUSNESS	45
11.3 INTENSITY	45
11.4 RELATIONSHIP TO STUDY MEDICATION	46

11.5 REPORTING OF ADVERSE EVENTS	46
11.6 TIMELINES AND REPORTING OF SAE	46
11.7 UNRESOLVED EVENTS	47
11.8 PREGNANCY REPORT FORM	47
11.9 DIRECT ACCESS TO SOURCE DATA/DOCUMENTS	48
12 DATA HANDLING	49
12.1 DATA MANAGEMENT	49
13 STATISTICAL METHODS	50
13.1 ESTIMATION OF SAMPLE SIZE	50
13.2 STATISTICAL ANALYSES	50
13.2.1 <i>Data Sets to be Analyzed</i>	50
13.2.2 <i>Statistical and Analytical Plan</i>	51
13.2.3 <i>Hypotheses and Statistical Methods</i>	51
13.2.4 <i>Level of Significance, Multiple Comparisons and Multiplicity</i>	53
13.2.5 <i>Adjustment for Covariates</i>	54
13.2.6 <i>Handling of Dropouts and Missing Data</i>	54
13.2.7 <i>Multicenter Studies</i>	54
13.2.8 <i>Examination of Subgroups</i>	54
13.2.9 <i>Interim Analysis and Data Monitoring</i>	54
13.2.10 <i>Deviation(s) from the Statistical Analysis Plan</i>	54
14 REGULATORY AND ADMINISTRATIVE PROCEDURES	55
14.1 ETHICS COMMITTEES AND COMPETENT AUTHORITIES	55
14.2 PATIENT INFORMATION / INFORMED CONSENT	56
14.3 PATIENT CONFIDENTIALITY	56
14.4 PATIENT TREATMENT PLAN	56

14.5 GCP	57
14.6 RECORD RETENTION	57
14.7 MONITORING / QUALITY CONTROL	57
14.8 SOURCE DATA	57
14.9 QUALITY ASSURANCE AND INSURANCE	58
15 END OF TRIAL	59
15.1 STUDY REPORT	59
15.2 STUDY STOPPING CRITERIA	59
15.3 PUBLICATION	59
16 LIST OF REFERENCES	60
17 SIGNATURES	64
18 CLINICAL STUDY PROTOCOL AGREEMENT FORM	65
LIST OF TABLES	
Table 1 Schedule of Patient Visits	23
Table 2 Schedule of Study Events	24